<<<what is the scope (business scope) of the verdict and what is immediate impact to Insmed doing business>>>
....and how is a patent lawyer going to answer this for you? there is no way to know how or what a jury will decided. Face it, this is a complete unknown.
You have to decide if you believe that this company has a product or not. If it doesn't, then sell. If it does, then decide if you want to ride the storm.
Last summer, Insmed share holders watched as the pps was taken to 75 cents. That was absurd for a company with an NDA in review. Tercica posted an 8k claiming that the FDA had stated that the two drugs were considered identical for orphan status. That was not correct. In fact, it was a down right lie. You are letting Tercica's PR affect your judgement. Are you sure you want to do that?
News 
Market Data 
Discover 
